Group Biomedical Sciences News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Group Biomedical Sciences. Real-time updates on events, politics, business and more.

Galapagos NV: Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn's disease

February 8, 2023

The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints

Region Flamande United Kingdom Northern Ireland Great Britain Daniele Dambrosio Van Gijsel

Source: finanznachrichten.de

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn's disease

February 8, 2023

Investegate announcements from Galapagos NV, Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

Region Flamande United Kingdom Northern Ireland Great Britain Daniele Dambrosio Van Gijsel

Source: investegate.co.uk

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Group Biomedical Sciences News Today

Galapagos NV: Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn's disease

Investegate |Galapagos NV Announcements | Galapagos NV: Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn's disease

Explore More Categories